Immuneering (NASDAQ:IMRX) Announces Quarterly Earnings Results

Immuneering (NASDAQ:IMRX) issued its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16), Zacks reports.

Immuneering Price Performance

NASDAQ IMRX opened at $1.65 on Friday. Immuneering has a 1-year low of $1.00 and a 1-year high of $3.83. The firm has a market capitalization of $51.23 million, a P/E ratio of -0.84 and a beta of -0.32. The business’s 50-day simple moving average is $1.80 and its 200-day simple moving average is $1.98.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on IMRX shares. Chardan Capital reiterated a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of Immuneering in a research report on Thursday, February 6th.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.